NY-ESO-1 (155-163)

NY-ESO-1 (155-163) is a synthetic peptide fragment derived from the NY-ESO-1 cancer-testis antigen, specifically encompassing amino acid residues 155 to 163. As a well-characterized epitope, it holds particular significance in the field of tumor immunology and antigen-specific immune response research. The peptide is widely utilized for its ability to mimic a naturally processed segment of the NY-ESO-1 protein, which is known for its restricted expression in normal tissues and widespread presence in various tumor types. Its defined sequence and immunogenic properties make it a valuable tool for studies aiming to elucidate mechanisms of antigen recognition, T cell activation, and the development of immunotherapeutic strategies.

Epitope mapping: Researchers frequently employ this peptide in epitope mapping studies to identify and characterize the specific regions of NY-ESO-1 recognized by cytotoxic T lymphocytes (CTLs). By utilizing the 155-163 fragment in in vitro assays, investigators can determine T cell receptor specificity, analyze cross-reactivity with related peptides, and dissect the fine specificity of immune responses in the context of tumor antigens. Such mapping is critical for understanding immune surveillance and for the rational design of targeted immunotherapies.

T cell activation assays: The peptide serves as a model antigen in T cell activation and functional assays, including ELISPOT, intracellular cytokine staining, and proliferation assays. When presented by appropriate HLA molecules on antigen-presenting cells, it can stimulate antigen-specific CD8+ T cells, enabling the assessment of T cell functionality, avidity, and cytotoxic potential. These studies are fundamental for evaluating the immunogenicity of NY-ESO-1-derived epitopes and for monitoring patient immune responses in vaccine or adoptive cell therapy research.

Immunomonitoring: Utilization of the NY-ESO-1 (155-163) peptide is instrumental in immunomonitoring protocols, particularly for tracking the frequency and activity of antigen-specific T cells in peripheral blood or tumor infiltrates. Peptide-MHC tetramer staining and flow cytometric analyses allow for the direct visualization and quantification of NY-ESO-1-specific T cell populations, providing valuable data on immune dynamics during disease progression or following immunotherapeutic interventions. This application supports the development of biomarkers for response assessment and patient stratification.

Vaccine development research: The defined immunogenicity of this peptide makes it a key component in preclinical vaccine development efforts. By incorporating the 155-163 epitope into peptide-based vaccine formulations, researchers can evaluate its capacity to elicit robust and specific cellular immune responses in vitro and in animal models. These studies inform the optimization of vaccine design, adjuvant selection, and delivery strategies for cancer immunoprevention and immunotherapy research.

Antigen processing and presentation studies: The peptide is also valuable in dissecting the molecular mechanisms underlying antigen processing and presentation by major histocompatibility complex (MHC) class I molecules. By introducing the synthetic epitope into cell-based systems, researchers can investigate proteasomal cleavage, peptide transport, and loading onto MHC molecules, thereby gaining insight into factors that influence antigen presentation efficiency and immune recognition. Such mechanistic studies are essential for advancing the understanding of tumor immune evasion and for identifying new targets for therapeutic intervention.

1. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

2. Olfactory receptor based piezoelectric biosensors for detection of alcohols related to food safety applications

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. Myotropic activity of allatostatins in tenebrionid beetles

5. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients